The core of the legal challenge centers on claims that Unicycive Therapeutics failed to verify the operational standards of its third-party manufacturing facilities. According to the complaint, the firm neglected to audit these sites for current good manufacturing practices, leaving them without a factual basis to claim that FDA-cited deficiencies had been resolved. This lack of oversight allegedly created an undisclosed risk that the agency would demand additional information, jeopardizing the regulatory approval timeline for the drug OLC.

By failing to disclose these operational gaps, the company’s public assertions regarding its business prospects were arguably deceptive. Shareholders seeking to participate in the class action or discuss their legal standing may contact Howard G. Smith at 215-638-4847 or via the firm's website. Participation in the lawsuit does not require immediate action, as investors may choose to retain their own counsel or remain absent class members.